Results 161 to 170 of about 391,028 (345)

Mapping Menstrual Health Research in France: A Scoping Review of Peer-Reviewed Literature Up to 2024

open access: yesInternational Journal of Women's Health
Violeta Alarcão,1,2 Elise de La Rochebrochard3,4 1Centre for Research and Studies in Sociology, Iscte— University Institute of Lisbon, Lisbon, Portugal; 2Institute of Environmental Health, Faculty of Medicine, University of Lisbon, Lisbon, Portugal ...
Alarcão V, de La Rochebrochard E
doaj  

Essential Labor

open access: yesPanorama, 2022
Michelle Millar Fisher
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

open access: yesMolecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Knowledge and involvement of husbands in the reproductive rights of women in Harar, eastern Ethiopia. [PDF]

open access: yesSAGE Open Med, 2021
Mohammed A   +6 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy